The telehealth sector, which includes major players such as Teladoc and Doximity, is projected to reach an impressive $504.24 billion by 2030, growing at a 19.7% compound annual growth rate (CAGR). This surge underscores the increasing reliance on virtual healthcare platforms and the pivotal role companies like Teladoc Health Inc. play, as shown by their notable year-over-year sales growth.
This article highlights the top telehealth companies—including Teladoc, CVS Health, Doximity, iRhythm Technologies, and Hims & Hers Health—that are shaping the future of virtual care. With strong financials and strategic expansions, these businesses stand out as promising investments in the rapidly growing digital health market.
Also see: Investing in Cannabis: The Best 5-Star Stocks for 2024
Teladoc Health Inc. (NYSE: TDOC)
Teladoc Health Inc. is a pioneer in digital health services with a diversified portfolio that makes it a top contender in the telehealth space.
Financial Overview
- Revenue (2023): $2.60 billion — an 8.13% increase from the previous year.
- Net Losses: Reduced significantly to -$220.37 million, a 98.39% reduction.
Market Performance
- Despite market headwinds, TDOC stock has potential for a 50.42% growth to a target price of $23.21.
Strategic Moves
- Expansion: New initiatives in obesity and weight management underline Teladoc’s effort to broaden service offerings.
- Acquisition: The acquisition of Livongo supports Teladoc’s ambition to lead in chronic care and virtual primary care.
Analyst Outlook
- Consensus: Strong ‘Buy’ rating.
- Forecast: A projected 113.34% price increase over the next year positions TDOC as a high-growth stock.
Summary: Teladoc Health’s strategic expansions and improved financials make it a compelling choice for investors eyeing the telehealth market.
CVS Health Corporation (NYSE: CVS)
CVS Health Corp. has successfully integrated telehealth into its MinuteClinics and Aetna health plans, enhancing patient access to virtual care services.
Stock Performance & Predictions
- Current Price (March 2024): $75.94
- Forecasts: Projected to reach $90 by end of 2024, and potentially $191.25 by 2035.
Analyst Ratings
- 40% rate CVS a ‘Strong Buy’, and 50% recommend a ‘Buy’.
Financial Forecasts
- Revenue Growth: Expected to reach $370.2 billion in the next year (+3.48%).
- Earnings Growth: Forecasted at 37.17%, outperforming the industry average.
Summary: Despite recent declines, CVS Health’s telehealth strategy and financial projections suggest strong potential for long-term growth.
Doximity Inc. (NYSE: DOCS)
Doximity Inc. connects over 80% of U.S. physicians and features a telehealth platform used by more than 360,000 providers.
Financial Overview
- Q3 2024 Revenue: $135.3 million (+17% YoY)
- EPS (TTM): 0.67
- PE Ratio (TTM): 41.34
Key Highlights
- Q2 FY24 Revenue: $113.6 million (+11% YoY)
- Profitability: Net income margin of 27%, and 48% EBITDA margin.
- User Adoption: Over 550,000 providers used Doximity tools in Q2 FY24.
Forecast & Outlook
- Short-term stock prediction shows a dip to $24.51, but long-term revenue and earnings are expected to grow at 8.4% and 9.7%, respectively.
- Despite high valuation, Doximity’s intrinsic value is 29% higher than its share price, suggesting room for growth.
Summary: With its strong provider network and solid financials, Doximity remains a key player in the telehealth landscape.
iRhythm Technologies Inc. (NASDAQ: IRTC)
iRhythm Technologies Inc. is gaining traction with its cardiac monitoring solutions powered by AI.
Stock Forecast
- Current Price (March 2024): $107.37
- 1-Year Target: $212.12 (+97.56%)
- 5-Year Target: $903.95
Analyst Ratings
- Rated a strong buy, with a price target of $130.17 (+21.33%).
Financial Growth
- 2024 Revenue Projection: $492.7 million
- Three-Year Forecast: $810.1 million (+64.43%)
Summary: iRhythm’s focus on AI-driven cardiac monitoring and impressive revenue projections make it a promising investment in digital health.
Hims & Hers Health Inc. (NYSE: HIMS)
Hims & Hers Health Inc. is rapidly expanding with a strong DTC telehealth model and notable customer growth.
Performance Metrics
- YTD Stock Increase: +41%
- Q3 2023 Revenue: $226.7 million (+57% YoY)
- Subscribers: 1.4 million
Stock Forecast
- Current Price (March 2024): $14.47
- Short-Term Target: $15.14 (March 2024), $23.73 (July 2024)
- Long-Term Target: $23.92 by 2024, and $50 by 2034
Analyst Consensus
- Rated Moderate Buy with a target range of $10.00 to $17.00
Summary: With substantial growth and a growing subscriber base, Hims & Hers is well-positioned in the telehealth space.
Conclusion
The telehealth industry is experiencing rapid transformation, with companies like Teladoc, CVS Health, Doximity, iRhythm, and Hims & Hers leading the way. These firms are not only increasing revenue but also reshaping how healthcare is delivered through digital innovation and strategic expansion.
The sector’s projected valuation of over $500 billion by 2030 emphasizes the lasting importance of virtual care in modern healthcare systems. For investors, these top telehealth stocks offer promising opportunities for long-term gains.
FAQs
What are the top telehealth stocks to invest in?
Some of the top telehealth stocks include:
- Teladoc Health (TDOC)
- Doximity (DOCS)
- CVS Health (CVS)
- GoodRx (GDRX)
- Amwell (AMWL)
Which stocks are expected to be the best investment in 2024?
Potential top-performing stocks for 2024 include:
- Walt Disney Company (DIS)
- PDD Holdings Inc. (PDD)
- Occidental Petroleum Corp. (OXY)
- Match Group Inc. (MTCH)
- Target Corp. (TGT)
- Pimco 25+ Year Zero Coupon ETF (ZROZ)
- Citigroup Inc. (C)
Which healthcare stocks are recommended for investment?
While this article focuses on telehealth, investment-worthy healthcare stocks should be evaluated based on:
- Market trends
- Company performance
- Future growth potential
Always consult a financial advisor before investing.
Who is the top provider in the telehealth industry?
Teladoc Health is considered the largest telehealth provider by revenue and workforce, according to Ampliz analysis.
